CBIO NASDAQ
Crescent Biopharma, Inc.
1W: +3.2%
1M: -8.8%
3M: -22.4%
YTD: +15.2%
1Y: -0.2%
3Y: -90.2%
5Y: -93.4%
$13.27
+0.51 (+4.00%)
After Hours: $14.93 (+1.66, +12.55%)
Weekly Expected Move ±9.0%
$11
$12
$13
$14
$15
Credit Risk of going bust: lower than 71% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-04-21
Earliest Filing
2025-12-04
Latest Filing
partner: 4
target: 3
supplier: 1
Counterparties (Filed by CBIO)
8 relationshipsCompanies named in CBIO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | — | partner | Entered into license agreements for CR-001 in Greater China and SKB105 in all other territories. | 2025-12-04 | View |
| Paragon Therapeutics, Inc. | — | partner | Licensee of CR-001; subject to amendment to align with sublicense to Kelun-Biotech. | 2025-12-04 | View |
| Nano Dimension USA Inc. | NNDM | supplier | Lease agreement for office space | 2025-06-18 | View |
| Crescent Biopharma, Inc. | CBIO | target | Target company in the proposed merger agreement with GlycoMimetics, Inc. | 2025-04-29 | View |
| Crescent Biopharma, Inc. | CBIO | target | Target company in a merger agreement and securities purchase agreement with GlycoMimetics, Inc. | 2025-02-14 | View |
| Crescent Biopharma, Inc. | CBIO | target | Target company in the merger agreement with GlycoMimetics, Inc. | 2024-10-29 | View |
| ARE-Maryland No. 45, LLC | — | partner | Third Amendment to Lease Agreement for office space in Rockville, Maryland | 2023-04-21 | View |
| BMR-Medical Center Drive LLC | — | partner | Original landlord that conveyed premises to ARE-Maryland No. 45, LLC | 2023-04-21 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-15 | Other Events | View | |
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-07-15 | Other Events; Exhibits | View | |
| 2026-07-14 | Earnings Release | View | |
| 2026-06-03 | Shareholder Vote | View | |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-04 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-06-18 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Result | Agreement Acquisition | View |
| 2025-06-06 | Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure; Other Events; Financi | View | |
| 2025-05-30 | Other Events | View | |
| 2025-04-29 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-02-25 | Termination of Material Definitive Agreement; Departure/Election of Directors; Appointment of Office | View | |
| 2025-02-14 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-01-31 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-12-26 | Notice of Delisting or Transfer | View | |
| 2024-11-07 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR